MET-amplified advanced NSCLC responds well to MET inhibitor capmatinib Presented ByProf. Jürgen Wolf, University Hospital Cologne, Germany TrialPhase 2, GEOMETRY ConferenceASCO 2020 8 September, 2020 13:07
